-
Democrats, Trump hold final rallies before midterm elections
-
African players in Europe: Defender Hakimi's historic hat-trick
-
Japan urges US to enforce discipline after second Marine arrest
-
Struggling Slavia face Arsenal as grim record looms
-
'Remarkable' rookie Lendeborg scores 37 as Warriors beat Clippers
-
Vikings suffer first loss while Broncos edge Chiefs in NFL
-
ExxonMobil urged to re-think Papua New Guinea gas project
-
South Korea to double spending on AI and chips in 2027
-
Asian stocks mixed as tech sector struggles to rebound from selloff
-
On All Saints' Day, Philippine mountain town honours dead with fire
-
India's royals find new power in their past
-
Years on from fall of IS, French jihadists face justice in Iraq
-
Irish bookshops help meet UK demand for Sally Rooney novels
-
Point of Law favourite at Australia's 'race that stops a nation'
-
NFL Vikings suffer first loss while Broncos edge Chiefs
-
'Kid' Antonelli gets affectionate tributes from all quarters
-
Host of fresh faces in Australia white-ball squads to face England
-
Hamilton accuses Leclerc of wrecking Ferrari hopes
-
NFL linebacker Campbell to remain hospitalized overnight
-
Chervon Names Jody Grimsley Senior National Account Manager
-
BioLargo's Clyra Medical Gains Commercial Traction as Clinician Enthusiasm Drives Health System Adoption
-
enVVeno Medical to Showcase the enVVe System at 38th Annual Transcatheter Cardiovascular Therapeutics (TCT) Scientific Symposium
-
Gladstone Alternative Income Fund Announces Monthly Cash Distribution for November 2026
-
Nexscient Announces Expanded Customer Engagements and New Commercial Agreements in Autonomous Driving and Humanoid Robotics Data Services
-
Vicapsys Life Sciences Provides Shareholder Update on VICAPSYN(TM) Program Advancing Toward Phase 1 Human Clinical Trial, Vertically Integrated With the Company's Indian Health Service Strategy
-
XCF Global Withdraws Reverse Stock Split Proposal; Reaffirms Growth Strategy and Shareholder Support
-
Gladstone Commercial Corporation Earnings Call and Webcast Information
-
cbdMD Completes Acquisition of the Operating Assets and Brands of Twinlab, including Twinlab, Reserveage and Metabolife Brands, Expanding Into Broader Wellness
-
Palo Alto Collaboration Company Opens Waitlist for Pana, a Personal AI That Builds Tools That Stay Yours
-
Anthony, Linder & Cacomanolis Recognized in Chambers & Partners Spotlight Florida 2027 for Securities Law Excellence
-
Tectonic Metals Intersects 5.61 g/t Au Over 41.15 m, Including 12.94 g/t Au Over 13.72 m, Within 2.86 g/t Au Over 91.44 m, Strengthening Evidence for a Second Gold System at the Flat Gold Project
-
IRS Pushes Tax Deadlines to February 1, 2027 for Washington Wildfire Counties - Clear Start Tax Explains What the Postponement Does Not Pause
-
Optimistivity Unveils Refreshed Brand and Expanded Digital Product Range
-
GameSquare to Report Q3 2026 Financial Results on November 16, 2026
-
AsiaFIN Holdings Corp. to Host Q3 2026 Earnings Webcast from New York City
-
Predictiv AI Awarded Metrolinx Master Agreement for On-Demand Transit Software and Related Services
-
Electric Metals (USA) Limited Announces Results of Annual Meeting of Stockholders
-
iAsk.ai Surpasses One Billion Searches
-
International Battery Metals Announces Second Quarter Fiscal 2027 Financial Results Conference Call and Webcast
-
Electrovaya Ranks Fourth Among Canada's Enterprise - Industry Leaders in Deloitte's Technology Fast 50(TM) Program
-
BEING rather than HAVING. A fascinating, practical STORY.
-
Hospital AI Funding Faces a Reality Check: New 2027 Outlook Puts Outsourcing Savings to the Test
-
Jaguar Mining Provides Update on Permitting of the Onças de Pitangui Development Project, Minas Gerais, Brazil
-
Ur-Energy Announces Retirement of CFO Roger Smith, Names VP Finance Jade Walle as Successor
-
DataMEDS AI Enters Into Agreement for Commercial Supply of Six Peptides Recommended by FDA Advisory Committee
-
Aer Lingus and MTech Mobility Launch Live Ground Operations Technology Programme Across Three Irish Airports
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 02
-
Bank of San Francisco Reports Third Quarter 2026 Financial Results
-
Aegis Capital Corp. Announces the Hiring of a New Managing Director
-
Foundation Software Announces Keynote Speakers for Its All-User Conference, CONVERGE27
California start-up sends tiny robots on voyage into brains
Sending miniature robots deep inside the human skull to treat brain disorders has long been the stuff of science fiction -- but it could soon become reality, according to a California start-up.
Bionaut Labs plans its first clinical trials on humans in just two years for its tiny injectable robots, which can be carefully guided through the brain using magnets.
"The idea of the micro robot came about way before I was born," said co-founder and CEO Michael Shpigelmacher.
"One of the most famous examples is a book by Isaac Asimov and a film called 'Fantastic Voyage,' where a crew of scientists goes inside a miniaturized spaceship into the brain, to treat a blood clot."
Just as cellphones now contain extremely powerful components that are smaller than a grain of rice, the tech behind micro-robots "that used to be science fiction in the 1950s and 60s" is now "science fact," said Shpigelmacher.
"We want to take that old idea and turn it into reality," the 53-year-old scientist told AFP during a tour of his company's Los Angeles research and development center.
Working with Germany's prestigious Max Planck research institutes, Bionaut Labs settled on using magnetic energy to propel the robots -- rather than optical or ultrasonic techniques -- because it does not harm the human body.
Magnetic coils placed outside the patient's skull are linked up to a computer that can remotely and delicately maneuver the micro-robot into the affected part of the brain, before removing it via the same route.
The entire apparatus is easily transportable, unlike an MRI, and uses 10 to 100 times less electricity.
- 'You're stuck' -
In a simulation watched by AFP, the robot -- a metal cylinder just a few millimeters long, in the shape of a tiny bullet -- slowly follows a pre-programed trajectory through a gel-filled container, which emulates the density of the human brain.
Once it nears a pouch filled with blue liquid, the robot is swiftly propelled like a rocket and pierces the sack with its pointed end, allowing liquid to flow out.
Inventors hope to use the robot to pierce fluid-filled cysts within the brain when clinical trials begin in two years.
If successful, the process could be used to treat Dandy-Walker Syndrome, a rare brain malformation affecting children.
Sufferers of the congenital ailment can experience cysts the size of a golf ball, which swell and increase pressure on the brain, triggering a host of dangerous neurological conditions.
Bionaut Labs has already tested its robots on large animals such as sheep and pigs, and "the data shows that the technology is safe for us" human beings, said Shpigelmacher.
If approved, the robots could offer key advantages over existing treatments for brain disorders.
"Today, most brain surgery and brain intervention is limited to straight lines -- if you don't have a straight line to the target, you're stuck, you're not going to get there," said Shpigelmacher.
Micro-robotic tech "allows you to reach targets you were not able to reach, and reaching them repeatedly in the safest trajectory possible," he added.
- 'Heating up' -
The US Food and Drug Administration (FDA) last year granted Bionaut Labs approvals that pave the way for clinical trials to treat Dandy-Walker Syndrome, as well as malignant gliomas -- cancerous brain tumors often considered to be inoperable.
In the latter case, the micro-robots will be used to inject anti-cancer drugs directly into brain tumors in a "surgical strike."
Existing treatment methods involve bombarding the whole body with drugs, leading to potential severe side effects and loss of effectiveness, said Shpigelmacher.
The micro-robots can also take measurements and collect tissue samples while inside the brain.
Bionaut Labs -- which has around 30 employees -- has held discussions with partners for the use of its tech to treat other conditions affecting the brain including Parkinson's, epilepsy or strokes.
"To the best of my knowledge, we are the first commercial effort" to design a product of this type with "a clear path to the clinic trials," said Shpigelmacher.
"But I don't think that we will be the only one... This area is heating up."
L.Mason--AMWN